In A02, M. Sos will study the role of MYC paralog activation in SCLC. We will use orthogonal genomic and computational methods to quantify the impact of individual MYC paralogs on the tumorigenesis of SCLC. Furthermore, we will employ CRISPRa/dCas9 based cellular SCLC models and pharmacological perturbation experiments to identify MYC paralog specific vulnerabilities in these tumors.
University Hospital of Cologne, University of Cologne
Molecular Pathology, Institute for Pathology
Department of Translational Genomics